期刊文献+

铁超负荷与非酒精性脂肪性肝病关系的研究进展 被引量:2

Relationship between iron overload and nonalcoholic fatty liver disease
下载PDF
导出
摘要 肝脏是储存多余铁的主要器官,因此当铁超负荷时,肝脏也是首先受到损害的靶器官。尽管铁超负荷与非酒精性脂肪性肝病之间的关系仍存在争论,但越来越多的研究表明,铁超负荷在非酒精性脂肪肝的发展过程中起到了一定作用:铁离子不但可以诱发氧化应激和脂质过氧化,还会引发胰岛素抵抗,从而加重非酒精性脂肪性肝病。 As the main organ of storing excess iron, liver is the first target organ damage when iron overload. However, the relation between nonalcoholic fatty liver disease and iron overload is still controversial. More and more studies have shown that iron overload in the development of nonalcoholic fatty liver played a role: not only iron-induced oxidative stress and lipid peroxidation, hut also lead to insulin resistance, thereby aggravating the non-alcoholic fatty liver.
作者 谭鹏 吴万春
出处 《胃肠病学和肝病学杂志》 CAS 2009年第6期578-580,共3页 Chinese Journal of Gastroenterology and Hepatology
关键词 非酒精性脂肪性肝病 铁超负荷 胰岛素抵抗 氧化应激 Nonalcoholic fatty liver disease Iron overload Insulin resistance Oxidative stress
  • 相关文献

参考文献23

  • 1Fatty Liver and Alcoholic Liver Disease Study Group of the Chinese Liver Disease Association..非酒精性脂肪性肝病诊疗指南[J].中华肝脏病杂志,2006,14(3):161-163. 被引量:1513
  • 2WANG LiDong1, ZHOU Qi1, WEI JunPing1, YANG WanCai1, ZHAO Xin1, WANG LiXia1, ZOU Jian Xiang1, GAO ShanShan1, LI YongXin1 and YANG C.S.2Keywords esophageal neoplasms,apoptosis,precancerous lesions,Waf1 p21 gene,p53.Apoptosis and its relationship with cell proliferation,p53,Waf1p21,bcl-2 and c-mycin esophageal carcinogenesis studied with a high-risk population in northern China[J].World Journal of Gastroenterology,1998,4(4):15-21. 被引量:299
  • 3Le Gac G, Ferec C. The molecular genetics of haemochromatosis [ J ]. EurJ Hum Genet, 2005, 13(11):1172-1185.
  • 4Bacon BR, Farahvash M J, Janney CG, et al. Nonalcoholic steatohepatitis: An expanded clinical entity [ J]. Gastroenterology, 1994, 107 (4) : 1103-1109.
  • 5Yamamoto M, lwasa M, lwata K, et al. Restriction of dietary calories, fat and iron improves non-alcohollc fatty liver disease [J]. J Gastroenterol Hepatol, 2007, 22(4): 498-503.
  • 6黄聪武,白岚,崔生达,蔡俊杰.血清铁、铁蛋白和脂肪肝关系的研究[J].中华消化杂志,2003,23(4):211-212. 被引量:23
  • 7弭希峰,黄子成,王木成,李水淼.非酒精性脂肪肝患者血清铁、转铁蛋白、血清铁蛋白水平测定[J].上海医药,2006,27(11):517-518. 被引量:13
  • 8Bonkovsky HL, Jawaid Q, Tortorelli K, et al. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis [ J ]. J Hepatol, 1999, 31 (3) : 421-429.
  • 9Fargion S, Mattioli M, Fracanzani AL, et al. Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis [ J ]. Am J Gastroenterol, 2001, 96 (8) : 2448-2455.
  • 10Aigner E, Theurl I, Theurl M, et al. Pathways underlying iron accumulation in human nonalcoholic fatty liver disease [ J]. Am J Clin Nutr, 2008, 87(5):1374-1383.

二级参考文献37

  • 1胡国平,刘凯,赵连三.多烯磷脂酰胆碱(易善复)治疗酒精性肝病和脂肪肝的系统评价[J].肝脏,2005,10(1):5-7. 被引量:108
  • 2Rouach H, Fataccioli V, Gentil M, et al. Effect of chronic ethanol feeding on lipid peroxidation and protein oxidation in relation to liver pathology. Hepatology, 1997, 25:351-355.
  • 3George DK, Goldwurm S, Mac Donald GA, et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology, 1998, 114:311-318.
  • 4Graudal N, Milman N, Galloe AM, et al. Distribution of liver haemosiderin iron in 187 patients with various types of hepatic deseases. APMIS, 1996, 104:220-226.
  • 5Wixom RL, Prutkin L, Munro HN. Hemosiderin: nature, formation, and significance. Int Rev Exp Pathol, 1980,22:193-225.
  • 6Tsukamoto H, Home W, Kami mura S, et al. Experimental liver cirrhosis induced by alcohol and iron. J Clin Invest, 1995,96:620-630.
  • 7Schwimmer JB,Behling C,Newbury R,et al.Histopathology of pediatric nonalcoholic fatty liver disease.Hepatology,2005,42:641-649.
  • 8Neuschwander Tetri BA,Caldwell SH.Nonalcoholic steatohepatitis:summary of an AASLD Single Topic Conference.Hepatology,2003,37:1202-1219.
  • 9Angulo P.Nonalcoholic fatty liver disease.N Engl J Med,2002,346:1221-1231.
  • 10Ghali P,Lindor KD.Hepatotoxicity of drugs used for treatment of obesity and its comorbidities.Semin Liver Dis,2004,24:389-397.

共引文献1817

同被引文献12

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部